Reckitt Unveils $600M Investment in NJ, NC Facilities
The consumer products manufacturer is building a new R&D center and nearly doubling the size of a manufacturing facility.
Reckitt, a global consumer health and hygiene brands company, is investing up to $600 million in New Jersey, where it will build a new R&D center, and in North Carolina, where it has significantly expanded plans for its largest over-the-counter manufacturing facility.
The multi-year plans at the two sites are meant to accelerate long-term growth of the U.K.-based company’s business and its U.S. operations. The investments are aimed at strengthening supply resilience for essential health-care products, according to the company. Reckitt’s top brands include Lysol, Mucinex and Finish dishwasher detergent.
READ ALSO: Top 10 Markets for Office Deliveries in H1 2026
The 145,000-square-foot science and innovation center will be built at the company’s new North American campus on the 116-acre ON3 mixed-use property in Nutley, N.J., owned by Prism Capital Partners. Reckitt said the innovation center will be a flagship germ protection hub within its global R&D network.
The new facility will have capabilities in disinfection microbiology, surface care, laundry care and personal care. It will replace another R&D center in nearby Montvale, N.J., according to The Wall Street Journal.
Reckitt relocated the North American headquarters to Nutley earlier this year from Parsippany, N.J., where it had been leasing space at the nearly 700,000-square-foot LATITUDE office complex owned by Rubenstein Partners and Vision Real Estate Partners. Reckitt signed a sublease late last year for 81,352 square feet of space at 100 Metro Blvd., a seven-story, 255,018-square-foot office building on the ON3 campus in Nutley, according to a report from Newmark.
Growing N.C. manufacturing capacity
The second major investment is taking place at Reckitt’s OTC manufacturing facility in Wilson, N.C., where it is expanding its initial $200 million investment. The company acquired the site in Wilson Corporate Park two years ago to move some production of its Mucinex products from factories in Mexico and the U.K., the WSJ reported.
Reckitt is doubling its investment from $200 to $400 million and increasing the size of the facility from 310,000 square feet to 544,000 square feet. It will become Reckitt’s largest OTC manufacturing facility in the U.S. when it opens in the first half of 2027.
In addition to significantly expanding the plant’s physical footprint, Reckitt noted the additional investment creates the space needed to support future growth, enhance manufacturing flexibility and accommodate new capabilities as demand evolve.
It will also expand production capacity of Mucinex tablets and liquids, as well as Move Free, its supplements line that supports joint, bone and cartilage health. The new manufacturing facility will enable Reckitt to produce more than 80 percent of the Mucinex product line in the U.S., according to the WSJ.
Founded in 1840, Reckitt operates in more than 80 countries and employs more than 36,000 people worldwide. In the U.S., Reckitt employes more than 4,000 employees at seven manufacturing sites and three science and innovation centers.
You must be logged in to post a comment.